Our study reveals that LURAP1L-AS1 is overexpressed in both TNBC and estrogen receptor-positive (ER+) breast cancer subtypes, and its elevated expression in TNBC correlates with poor patient survival. Here, LURAP1L is linked to breast carcinoma.